Atezolizumab (Tecentriq) ELISA

Atezolizumab (Tecentriq) ELISA

Product specifications

Species reactivity: Chemical

Host/Isotype: Rabbit / IgG

Class: monoclonal

Writes: Antibody

Clone: 43H11

Immunogen: atezolizumab

Conjugate: Unconjugated

Form: freeze-dried

Purification: protein A

Storage buffer: PBS, pH 7.4

Contains: 0.02% Sodium Azide

Storage conditions: -20°C or -80°C if preferred

Product specific information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. Atezolizumab is a fully-humanized monoclonal antibody that is approved by the US Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). It binds to the protein programmed cell death ligand 1 (PD-L1) in various tumours.

Atezolizumab has the ability to block the binding of PD-L1 to PD-1 and CD80 (B7-1R) receptors, which has a positive effect on improving the antitumor response. GenScript MonoRab™ Anti-Atezolizumab Antibody (43H11), mAb, Rabbit is produced from a hybridoma resulting from the fusion of B lymphocytes and associates obtained from a rabbit immunized with atezolizumab.

Destination information

Atezolizumab is a fully humanized IgG1 isotype monoclonal antibody designed against the programmed cell death ligand 1 (PD-L1) protein. Atezolizumab blocks the interaction of PD-L1 with the programmed cell death protein 1 (PD-1) and CD80 (B7-1R) receptors. PD-L1 can be highly expressed in certain tumours, which is thought to lead to reduced activation of immune cells (particularly cytotoxic T cells) that might otherwise recognize and attack cancer. Inhibition of PD-L1 by atezolizumab can eliminate this inhibitory effect and thus generate an antitumor response. It’s one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as “immune checkpoint inhibition.”

Leave a Reply

Your email address will not be published. Required fields are marked *